In his last blog, Dr. Borigini discussed the Rheumatoid Factor, its significance, and perhaps its insignificance. In this article he explains that the bottom line, however, is that rheumatologists are on a seemingly never-ending quest to find ways to predict who among patients will have a worse outcome, and are therefore, perhaps, deserving of being treated aggressively even before their clinical presentation shows aggressive disease. Read now to learn where Arava fits in Dr. Borigini's discussion.